These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19320570)

  • 1. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
    Hicks CB; DeJesus E; Sloan LM; Sension MG; Wohl DA; Liao Q; Ross LL; Pakes GE; Pappa KA; Lancaster CT;
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):395-403. PubMed ID: 19320570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
    Cohen C; Dejesus E; Lamarca A; Young B; Yau L; Patel L; Vavro C; Wire MB; Wannamaker P; Shaefer M
    HIV Clin Trials; 2010; 11(5):239-47. PubMed ID: 21126954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.
    Carosi ; Lazzarin ; Stellbrink ; Moyle ; Rugina ; Staszewski ; Givens ; Ross ; Granier ; Ait-Khaled ; Leather ; Nichols
    HIV Clin Trials; 2009; 10(6):356-67. PubMed ID: 20133266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
    Eron J; Yeni P; Gathe J; Estrada V; DeJesus E; Staszewski S; Lackey P; Katlama C; Young B; Yau L; Sutherland-Phillips D; Wannamaker P; Vavro C; Patel L; Yeo J; Shaefer M;
    Lancet; 2006 Aug; 368(9534):476-82. PubMed ID: 16890834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
    Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
    HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
    Blick G; Greiger-Zanlungo P; Gretz S; Han J; Dupree D; Garton T; Yau LH; Wine BC; Pakes GE;
    Int J STD AIDS; 2012 Mar; 23(3):e18-22. PubMed ID: 22581890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
    Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
    AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
    Podzamczer D; Imaz A; Perez I; Viciana P; Valencia E; Curto J; Martín T; Castaño M; Rojas J; Espinosa N; Moreno V; Asensi V; Iribarren JA; Clotet B; Force L; Bachiller P; Knobel H; López Bernaldo De Quirós JC; Blanco JR; Rozas N; Vergas J; Ocampo A; Camacho A; Flores J; Gomez-Sirvent JL;
    J Antimicrob Chemother; 2014 Sep; 69(9):2536-40. PubMed ID: 24833755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients.
    Wood R; Gathe JC; Givens N; Sedani S; Cheng K; Sievers J
    HIV Clin Trials; 2013; 14(5):183-91. PubMed ID: 24144895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Van Kasteren ME; Bravenboer B; Ten Kate RW; Groeneveld PH; van der Werf TS; Gisolf EH; Richter C
    AIDS Patient Care STDS; 2010 Jun; 24(6):361-6. PubMed ID: 20515418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
    Elion R; Dejesus E; Sension M; Berger D; Towner W; Richmond G; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2008; 9(3):152-63. PubMed ID: 18547902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir/lamivudine fixed-dose combination with ritonavir-boosted darunavir: a safe and efficacious regimen for HIV therapy.
    Trottier B; Machouf N; Thomas R; Gallant S; Longpré D; Vézina S; Boissonnault M; Lavoie S; Legault D; Dion H; Nguyen VK
    HIV Clin Trials; 2012; 13(6):335-42. PubMed ID: 23195671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
    Gathe JC; Ive P; Wood R; Schürmann D; Bellos NC; DeJesus E; Gladysz A; Garris C; Yeo J
    AIDS; 2004 Jul; 18(11):1529-37. PubMed ID: 15238771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
    Smith KY; Weinberg WG; DeJesus E; Fischl MA; Liao Q; Ross LL; Pakes GE; Pappa KA; Lancaster CT;
    AIDS Res Ther; 2008 Mar; 5():5. PubMed ID: 18373851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ; Sánchez-Conde M; Soriano V; Mallolas J; Luque I; Rodríguez-Alcántara F;
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.